Misonix (NASDAQ:MSON) announced its earnings results on Thursday. The medical equipment provider reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.09), Fidelity Earnings reports. The company had revenue of $9.36 million for the quarter. Misonix had a negative return on equity of 7.91% and a negative net margin of 20.75%.

Shares of MSON stock traded up $0.24 during mid-day trading on Friday, hitting $16.44. The company’s stock had a trading volume of 41,562 shares, compared to its average volume of 17,495. Misonix has a 52 week low of $8.25 and a 52 week high of $21.43.

Several research analysts recently issued reports on MSON shares. TheStreet lowered Misonix from a “c” rating to a “d+” rating in a research report on Friday, September 7th. Canaccord Genuity started coverage on Misonix in a research report on Friday, August 24th. They set a “buy” rating and a $24.00 target price for the company. Finally, Craig Hallum started coverage on Misonix in a research report on Tuesday, September 11th. They set a “buy” rating and a $28.00 target price for the company.

WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2018/11/10/misonix-mson-announces-quarterly-earnings-results-misses-estimates-by-0-09-eps.html.

Misonix Company Profile

Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.

Featured Story: Bull Market

Earnings History for Misonix (NASDAQ:MSON)

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.